Molecular testing of metastatic melanoma is currently the standard of care for guiding the use FDA-approved targeted therapies such as BRAF, MEK and KIT inhibitors. In addition, more investigational clinical actions are often employed for patients with metastatic melanoma including the use FDA-approved drugs for an off-label indication and enrollment in clinical trials. This assay is designed to provide comprehensive molecular results relevant for both standard of care and emerging/investigational clinical actions. This DNA and RNA based, next-generation sequencing test targets 50 genes to detect substitution and insertion/deletion mutations (35 genes), gene amplifications (19 genes), and gene fusions (21 genes). Detectable variants relevant for melanoma include, but are not limited to, mutations of BRAF, NRAS, KIT, MAP2K1, CTNNB1, GNAQ and GNA11; amplification of CCND1 and KIT; and rearrangements of BRAF, NTRK1, ROS1, ALK and RET. A complete list of sequenced regions, genes assessed for amplification and detectable fusion transcripts is available below.